Optimization of Glucocorticoid Therapy for Long-Term Treatment in Connective Tissue Diseases

Explore the optimization of glucocorticoid therapy for long-term treatment in Connective Tissue Diseases (CTDs) in this informative 48-minute webinar. Delve into the essential role of glucocorticoids (GCs) in managing life-threatening autoimmune diseases and their effectiveness as disease-modifying anti-rheumatic drugs (DMARDs) in slowing radiographic progression and articular damage. Learn about the importance of individualized GC use based on patient characteristics and the need to minimize dosage due to potential adverse effects. Discover the benefits of modified-release prednisone formulations for respecting circadian rhythms and mitigating nocturnal inflammation. Understand the significance of Treat-to-Target (T2T) strategies in setting disease activity targets and reducing or discontinuing GCs. Gain insights from Prof. Maurizio Cutolo, a renowned expert in rheumatology and internal medicine, on personalized GC therapy for optimal long-term outcomes in CTDs.

The optimization of glucocorticoid therapy for long term treatment in Connective Tissue Diseases